These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 8909331

  • 1. Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients.
    Allan ER, Alpert M, Sison CE, Citrome L, Laury G, Berman I.
    J Clin Psychiatry; 1996 Oct; 57(10):455-9. PubMed ID: 8909331
    [Abstract] [Full Text] [Related]

  • 2. Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients: a double-blind, placebo-controlled study.
    Ratey JJ, Sorgi P, O'Driscoll GA, Sands S, Daehler ML, Fletcher JR, Kadish W, Spruiell G, Polakoff S, Lindem KJ.
    J Clin Psychiatry; 1992 Feb; 53(2):41-6. PubMed ID: 1347291
    [Abstract] [Full Text] [Related]

  • 3. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
    Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG.
    Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196
    [Abstract] [Full Text] [Related]

  • 4. A double-blind, placebo-controlled study of adjunctive nadolol in the management of violent psychiatric patients.
    Alpert M, Allan ER, Citrome L, Laury G, Sison C, Sudilovsky A.
    Psychopharmacol Bull; 1990 Jun; 26(3):367-71. PubMed ID: 2274638
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials.
    Buckley PF.
    Curr Med Res Opin; 2004 Sep; 20(9):1357-63. PubMed ID: 15383183
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group.
    Borison RL, Arvanitis LA, Miller BG.
    J Clin Psychopharmacol; 1996 Apr; 16(2):158-69. PubMed ID: 8690831
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
    Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M.
    Arch Gen Psychiatry; 1999 Jan; 56(1):29-36. PubMed ID: 9892253
    [Abstract] [Full Text] [Related]

  • 11. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial.
    Josiassen RC, Joseph A, Kohegyi E, Stokes S, Dadvand M, Paing WW, Shaughnessy RA.
    Am J Psychiatry; 2005 Jan; 162(1):130-6. PubMed ID: 15625211
    [Abstract] [Full Text] [Related]

  • 12. Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia.
    Müller MJ, Wetzel H, Eich FX, Rein W, Puech A, Benkert O, Amisulpride Study Group.
    J Clin Psychopharmacol; 2002 Dec; 22(6):554-60. PubMed ID: 12454554
    [Abstract] [Full Text] [Related]

  • 13. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group.
    Kramer MS, Last B, Getson A, Reines SA.
    Arch Gen Psychiatry; 1997 Jun; 54(6):567-72. PubMed ID: 9193198
    [Abstract] [Full Text] [Related]

  • 14. The effect of quetiapine on aggression and hostility in patients with schizophrenia.
    Arango C, Bernardo M.
    Hum Psychopharmacol; 2005 Jun; 20(4):237-41. PubMed ID: 15830402
    [Abstract] [Full Text] [Related]

  • 15. The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes.
    Arango C, Breier A, McMahon R, Carpenter WT, Buchanan RW.
    Am J Psychiatry; 2003 Aug; 160(8):1421-7. PubMed ID: 12900303
    [Abstract] [Full Text] [Related]

  • 16. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
    Möller HJ, Riedel M, Müller N, Fischer W, Kohnen R.
    Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
    [Abstract] [Full Text] [Related]

  • 17. Vitamin B6 treatment in acute neuroleptic-induced akathisia: a randomized, double-blind, placebo-controlled study.
    Lerner V, Bergman J, Statsenko N, Miodownik C.
    J Clin Psychiatry; 2004 Nov; 65(11):1550-4. PubMed ID: 15554771
    [Abstract] [Full Text] [Related]

  • 18. ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia.
    Fabre LF, Arvanitis L, Pultz J, Jones VM, Malick JB, Slotnick VB.
    Clin Ther; 1995 Nov; 17(3):366-78. PubMed ID: 7585841
    [Abstract] [Full Text] [Related]

  • 19. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients.
    Spina E, De Domenico P, Ruello C, Longobardo N, Gitto C, Ancione M, Di Rosa AE, Caputi AP.
    Int Clin Psychopharmacol; 1994 Nov; 9(4):281-5. PubMed ID: 7868850
    [Abstract] [Full Text] [Related]

  • 20. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment.
    Wright P, Lindborg SR, Birkett M, Meehan K, Jones B, Alaka K, Ferchland-Howe I, Pickard A, Taylor CC, Roth J, Battaglia J, Bitter I, Chouinard G, Morris PL, Breier A.
    Can J Psychiatry; 2003 Dec; 48(11):716-21. PubMed ID: 14733451
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.